Combined interferon alpha with levamisole in patients with metastatic renal cell carcinoma

To evaluate the efficacy and toxicity of interferon alpha-2b (IFN-alpha2b) and levamisole treatment regimen in patients with metastatic renal cell carcinoma (RCC). Seventeen patients with metastatic RCC were treated using recombinant IFN-alpha2b at a dose of 10 MU/m2 body surface subcutaneously thre...

Full description

Saved in:
Bibliographic Details
Published in:International urology and nephrology 2001, Vol.33 (3), p.457
Main Authors: Aksoy, H, Baltaci, S, Türkölmez, K, Seçkiner, I, Bedük, Y
Format: Article
Language:English
Subjects:
Adjuvants, Immunologic - adverse effects
Adjuvants, Immunologic - therapeutic use
Adult
Aged
Antineoplastic Agents - adverse effects
Antineoplastic Agents - therapeutic use
Bone Neoplasms - drug therapy
Bone Neoplasms - secondary
Carcinoma, Renal Cell - drug therapy
Carcinoma, Renal Cell - secondary
Drug Therapy, Combination
Female
Humans
Interferon alpha-2
Interferon-alpha - adverse effects
Interferon-alpha - therapeutic use
Kidney Neoplasms - drug therapy
Kidney Neoplasms - pathology
Levamisole - adverse effects
Levamisole - therapeutic use
Lung Neoplasms - drug therapy
Lung Neoplasms - secondary
Male
Middle Aged
Recombinant Proteins
Treatment Outcome
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To evaluate the efficacy and toxicity of interferon alpha-2b (IFN-alpha2b) and levamisole treatment regimen in patients with metastatic renal cell carcinoma (RCC). Seventeen patients with metastatic RCC were treated using recombinant IFN-alpha2b at a dose of 10 MU/m2 body surface subcutaneously three times in a week, for 3 months, with levamisole 50 mg t.d.s orally on days 1-3 on alternate weeks. The mean follow-up period was 10.7 (range 2-23) months. We achieved 1 complete response (lasting for 12+ months) and 1 partial response (lasting for 15 months), for an objective response rate of 11.7%. A further 7 patients (41%) had a stabilization of disease. The overall toxicity was moderate, with mainly grade I or II side effects. Grade III toxicities reported among 3 patients including vomiting (2 patients) and anorexia (1 patient). There was no treatment related death. Although additions of levamisole to IFN-alpha do not result in any significant increase in treatment toxicity, the response rate appears to be no better than IFN-alpha monotherapy reported in the literature.
ISSN:0301-1623
1573-2584
DOI:10.1023/A:1019510628249